1100 Concurrent daily chemotherapy with hyperfractionated thoracic irradiation in stage IIIA & B NSCLC

In January 1993 we initiated a pilot study of concurrent daily chemotherapy with hyperfractionated thoracic irradiation in Stage III NSCLC. Twenty-four patients were entered on study. The following were the demographics: 15 males and 9 females; median age 62 (35–77); mean perfonnance status 0; histology—10 squamous, 3 adeno, 11 large cell carcinomas; stage—11 with IIIA, 12 with IIIB, 1 with IV. Chemotherapy consisted of CDDP 3mg/m2 daily (4 pts), 5mg/m2 daily (1 pt) and 6mg/m2 daily (19 pts), with weekly vinblastine 2mg/m2 (9 pts). Hyperfractionated thoracic irradiation 60 Gy in 40 fractions over 4 weeks at 1.5 Gy b.i.d. Four weeks post concurrent chemo-irradiation, 3 cycles of CDDP 75–80mg/m2 and vinblastine 8mg/m2 q 21 days were given. Overall response rate 18/24 (75%), CR 7/24 (29%), PR 11/24 (46%). Median time to progression 12.4 months, median survival 17.3 months. The major toxicity was esophagitis. The toxicity will be presented in detail.